Limits...
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E - Vaccines (Basel) (2014)

Bottom Line: HI and SRH are established and reproducible techniques, whereas VN is more demanding.Every new influenza vaccine needs to fulfil the strict criteria issued by the European Medicines Agency (EMA) in order to be licensed.These criteria currently apply exclusively to SRH and HI assays and refer to two different target groups-healthy adults and the elderly, but other vaccine recipient age groups have not been considered (i.e., children).

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro, 53100 Siena, Italy. trombetta@unisi.it.

ABSTRACT
Serological techniques commonly used to quantify influenza-specific antibodies include the Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) and Virus Neutralization (VN) assays. HI and SRH are established and reproducible techniques, whereas VN is more demanding. Every new influenza vaccine needs to fulfil the strict criteria issued by the European Medicines Agency (EMA) in order to be licensed. These criteria currently apply exclusively to SRH and HI assays and refer to two different target groups-healthy adults and the elderly, but other vaccine recipient age groups have not been considered (i.e., children). The purpose of this timely review is to highlight the current scenario on correlates of protection concerning influenza vaccines and underline the need to revise the criteria and assays currently in use. In addition to SRH and HI assays, the technical advantages provided by other techniques such as the VN assay, pseudotype-based neutralization assay, neuraminidase and cell-mediated immunity assays need to be considered and regulated via EMA criteria, considering the many significant advantages that they could offer for the development of effective vaccines.

No MeSH data available.


Related in: MedlinePlus

Relationship between HI and neutralizing antibody titres against A/Yamagata/12/86 (H1N1), A/Fukuoka/C29/85 (H3N2) and A/Shisen/2/87 (H3N2) [65].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494249&req=5

vaccines-02-00707-f002: Relationship between HI and neutralizing antibody titres against A/Yamagata/12/86 (H1N1), A/Fukuoka/C29/85 (H3N2) and A/Shisen/2/87 (H3N2) [65].

Mentions: Okuno et al. [65] have demonstrated a good correspondence between HI and VN titres in some circumstances and also report a heightened reliability of VN when compared to HI (Figure 2). They recorded both sets of titres raised against the seasonal influenza strains A/Yamagata/12/86 (H1N1), A/Fukuoka/C29/85 (H3N2) and A/Shisen/2/87 (H3N2). The results showed a good correlation between titres calculated for A/Yamagata/12/86 (H1N1) and A/Fukuoka/C29/85 (H3N2), but the VN titres were lower than those for HI against A/Shisen/2/87 (H3N2). An explanation of this is that, over recent years, most schoolchildren have received a multivalent vaccine including A/Yamagata/12/86 (H1N1) and A/Fukuoka/C29/85 (H3N2) strains, but not A/Shisen/2/87 (H3N2), since it was a candidate vaccine strain from 1988.


Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E - Vaccines (Basel) (2014)

Relationship between HI and neutralizing antibody titres against A/Yamagata/12/86 (H1N1), A/Fukuoka/C29/85 (H3N2) and A/Shisen/2/87 (H3N2) [65].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494249&req=5

vaccines-02-00707-f002: Relationship between HI and neutralizing antibody titres against A/Yamagata/12/86 (H1N1), A/Fukuoka/C29/85 (H3N2) and A/Shisen/2/87 (H3N2) [65].
Mentions: Okuno et al. [65] have demonstrated a good correspondence between HI and VN titres in some circumstances and also report a heightened reliability of VN when compared to HI (Figure 2). They recorded both sets of titres raised against the seasonal influenza strains A/Yamagata/12/86 (H1N1), A/Fukuoka/C29/85 (H3N2) and A/Shisen/2/87 (H3N2). The results showed a good correlation between titres calculated for A/Yamagata/12/86 (H1N1) and A/Fukuoka/C29/85 (H3N2), but the VN titres were lower than those for HI against A/Shisen/2/87 (H3N2). An explanation of this is that, over recent years, most schoolchildren have received a multivalent vaccine including A/Yamagata/12/86 (H1N1) and A/Fukuoka/C29/85 (H3N2) strains, but not A/Shisen/2/87 (H3N2), since it was a candidate vaccine strain from 1988.

Bottom Line: HI and SRH are established and reproducible techniques, whereas VN is more demanding.Every new influenza vaccine needs to fulfil the strict criteria issued by the European Medicines Agency (EMA) in order to be licensed.These criteria currently apply exclusively to SRH and HI assays and refer to two different target groups-healthy adults and the elderly, but other vaccine recipient age groups have not been considered (i.e., children).

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro, 53100 Siena, Italy. trombetta@unisi.it.

ABSTRACT
Serological techniques commonly used to quantify influenza-specific antibodies include the Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) and Virus Neutralization (VN) assays. HI and SRH are established and reproducible techniques, whereas VN is more demanding. Every new influenza vaccine needs to fulfil the strict criteria issued by the European Medicines Agency (EMA) in order to be licensed. These criteria currently apply exclusively to SRH and HI assays and refer to two different target groups-healthy adults and the elderly, but other vaccine recipient age groups have not been considered (i.e., children). The purpose of this timely review is to highlight the current scenario on correlates of protection concerning influenza vaccines and underline the need to revise the criteria and assays currently in use. In addition to SRH and HI assays, the technical advantages provided by other techniques such as the VN assay, pseudotype-based neutralization assay, neuraminidase and cell-mediated immunity assays need to be considered and regulated via EMA criteria, considering the many significant advantages that they could offer for the development of effective vaccines.

No MeSH data available.


Related in: MedlinePlus